Cormorant Asset Management, LP Uro Gen Pharma Ltd. Transaction History
Cormorant Asset Management, LP
- $1.43 Billion
- Q3 2024
A detailed history of Cormorant Asset Management, LP transactions in Uro Gen Pharma Ltd. stock. As of the latest transaction made, Cormorant Asset Management, LP holds 1,550,000 shares of URGN stock, worth $17.9 Million. This represents 1.38% of its overall portfolio holdings.
Number of Shares
1,550,000
Previous 1,650,000
6.06%
Holding current value
$17.9 Million
Previous $27.7 Million
28.9%
% of portfolio
1.38%
Previous 2.13%
Shares
2 transactions
Others Institutions Holding URGN
# of Institutions
130Shares Held
35.9MCall Options Held
22KPut Options Held
93.8K-
Rtw Investments, LP New York, NY3.79MShares$43.7 Million0.77% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.74MShares$43.1 Million0.09% of portfolio
-
Menora Mivtachim Holdings Ltd.2.3MShares$26.6 Million0.19% of portfolio
-
Black Rock Inc. New York, NY2.19MShares$25.3 Million0.0% of portfolio
-
Morgan Stanley New York, NY2.18MShares$25.2 Million0.0% of portfolio
About UroGen Pharma Ltd.
- Ticker URGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 22,740,500
- Market Cap $263M
- Description
- UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...